Thirst
For Life

Sylvant^® is currently licensed in EU, US and other countries worldwide including Canada, Korea and Mexico and is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with idiopathic multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. By binding to the IL-6 ligand, Sylvant^® therefore blocks the signaling cascade that would lead to proliferation of immune cells.

Caphosol^® is indicated for the treatment and prevention of oral mucositis, a complication of cancer treatment (including radiation and chemotherapy). It contains a high concentration of phosphate and calcium ions to lubricate the mucosa of the mouth, tongue and oropharynx and help maintain the integrity of the oral cavity. Caphosol^® is available as ampules or in dispersible form.

Qarziba^® is currently licensed in the EU for the treatment of high risk neuroblastoma, a rare form of cancer arising from neural crest cells, in patients aged 12 months and above. The molecule is a monoclonal chimeric antibody that binds to the GD2 antigen on neuroblastoma cells, and activates an immune response that targets these cancer cells.

Fotivda^® is a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI): an oral, once-daily inhibitor of all three vascular endothelial growth factor (VEGF) receptors. Fotivda^® is indicated in the EU for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naīve following disease progression after one prior treatment with cytokine therapy for advanced RCC.